EASTONBIOPHARMACEUTICALS(SH:688513)2024-10-24 08:16Financial Performance - The company's revenue for Q3 2024 reached ¥370,423,463.04, representing a year-on-year increase of 25.81%[1] - Net profit attributable to shareholders for Q3 2024 was ¥70,531,245.05, an increase of 13.40% compared to the same period last year[1] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥54,115,567.05, up 16.72% year-on-year[1] - Total operating revenue for the first three quarters of 2024 reached CNY 1,039,937,156.56, a 22.3% increase from CNY 849,780,066.91 in the same period of 2023[11] - Net profit for the third quarter of 2024 was CNY 217,023,597.92, up 12.0% from CNY 193,716,138.10 in the third quarter of 2023[12] - The company's total equity increased to CNY 2,677,009,418.36, compared to CNY 2,603,420,163.73 in the same period last year, reflecting a growth of 2.8%[10] - Basic and diluted earnings per share for the third quarter of 2024 were both CNY 1.24, compared to CNY 1.10 in the same quarter of 2023[13] Research and Development - R&D expenses totaled ¥84,022,423.15 in Q3 2024, marking a 33.73% increase compared to the same period last year[2] - The ratio of R&D expenses to revenue was 22.68%, an increase of 1.34 percentage points year-on-year[2] - Research and development expenses for the first three quarters of 2024 were CNY 188,129,351.01, an increase from CNY 168,765,644.63 in the same period of 2023[11] - The company continues to focus on expanding its market presence and enhancing its product offerings through ongoing research and development initiatives[16] Assets and Liabilities - Total assets at the end of the reporting period were ¥3,418,213,443.33, reflecting a 2.14% increase from the end of the previous year[2] - As of September 30, 2024, total assets amounted to RMB 3,418,213,443.33, an increase from RMB 3,346,754,293.88 at the end of 2023, reflecting a growth of approximately 2.1%[7] - Current assets totaled RMB 1,940,299,395.13, compared to RMB 1,882,871,229.64 at the end of 2023, indicating an increase of about 3.1%[8] - Total liabilities amounted to CNY 741,204,024.97, slightly down from CNY 743,334,130.15 in the previous year[10] - The total number of ordinary shareholders at the end of the reporting period was 4,464[5] Cash Flow - The net cash flow from operating activities for the first three quarters of 2024 is CNY 146,646,770.03, a decrease of 26% compared to CNY 197,748,590.40 in the same period of 2023[15] - Total cash inflow from operating activities amounted to CNY 1,027,032,791.52, up from CNY 928,523,523.06 year-on-year[15] - Cash outflow from operating activities totaled CNY 880,386,021.49, compared to CNY 730,774,932.66 in the previous year, reflecting a 20.5% increase[15] - The net cash flow from investing activities is -CNY 156,233,664.25, an improvement from -CNY 532,553,512.75 in the same period last year[15] - Cash inflow from investment activities reached CNY 1,275,405,844.97, while cash outflow was CNY 1,431,639,509.22[15] - Cash flow from financing activities resulted in a net outflow of -CNY 175,472,039.72, compared to a net inflow of CNY 34,584,325.09 in the previous year[15] - The ending balance of cash and cash equivalents is CNY 582,244,676.65, down from CNY 521,630,048.95 year-on-year[15] Other Financial Metrics - The weighted average return on equity (ROE) for Q3 2024 was 2.72%, an increase of 0.27 percentage points from the previous year[2] - The company reported a significant increase in tax payments, totaling CNY 101,485,163.59, compared to CNY 79,224,423.90 in the previous year[15] - The company has not reported any significant changes in the participation of major shareholders in margin trading or securities lending activities during the reporting period[7] - The company has not adopted new accounting standards for the current year, maintaining consistency in financial reporting[16]